Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human Fc gamma RIIA / CD32a (R167), Avi Tag (Avitag™), 25µg  

Recombinant Biotinylated Human Fc gamma RIIA / CD32a (R167), Avi Tag (Avitag™), 25µg

Biotinylated Human Fc gamma RIIA / CD32a (R167) Protein, Avitag™,His Tag (SPR & BLI verified)

Synonym
recombinant, human, biotinylated, protein, CD32a,FCGR2A,CD32,FCG2 ,FCGR2A1,IGFR2

More details

CDA-H82E7-25

Availability: within 7 days

420,00 €

Background
Receptors for the Fc region of IgG (Fc γ R) are members of the Ig superfamily that function in the activation or inhibition of immune responses. Three classes of human Fc γ Rs: RI (CD64), RII (CD32), and RIII (CD16), which generate multiple isoforms, are recognized. There are three genes for human Fcγ RII /CD32 (A, B, and C) and one for mouse Fcγ RII B (CD32B). CD32 is a low affinity receptor for IgG. The activating isoform, CD32A, is expressed on monocytes, neutrophils, platelets and dendritic cells. CD32A is expressed on many immune cell types (macrophage, neutrophil, eosinophils, platelets, dendritic cells and Langerhan cells), where inhibitory ITIM­bearing receptors may also be coexpressed and co­engaged by specific ligands. CD32A delivers an activating signal upon ligand binding, and results in the initiation of inflammatory responses including cytolysis, phagocytosis, degranulation and cytokine production. The responses can be modulated by signals from the coexpressed inhibitory receptors such as CD32B, and the strength of the signal is dependent on the ratio of expression of the activating and inhibitory receptors. 

Source
Biotinylated Human CD32a (R167), Avitag,His Tag (SPR & BLI verified) (CDA-H82E7) is expressed from human 293 cells (HEK293). It contains AA Ala 36 - Ile 218 (Accession # P12318-1).
Predicted N-terminus: Ala 36

Molecular Characterization
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 24.0 kDa. The protein migrates as 32-42 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22µm filtered solution in PBS (pH 7.4) with Trehalose as protectant.
Contact us for customized product form or formulation.

Reconstitution
Reconstitute at 100 μg/mL in sterile deionized water. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. No activity loss is observed after storage at: 4-8° C for 12 months in lyophilized state; -70° C for 3 months under sterile conditions after reconstitution.

Bioactivity
Measured by its binding ability in a functional ELISA against immobilized Yervoy Ipilimumab (1μg/well). The linear range is 0.15-10 μg/mL.

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrosbiosystems’s AviTagTM proteins confers to the purchaser the limited right to use the AviTagTM technology for non-commercial, or research use, or for purposes of evaluating the AviTagTM technology.
Commercial use of the AviTagTM technology to manufacture a commercial product, or use of the AviTagTM technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays. 

References

(1) Ravetch JV. et al., 2001, Annu Rev Immunol. 19: 275-83.
(2) Takai T. 2002, Nature Rev Immunol. 2: 580-92.
(3) Nagarajan S. et al., 2000, Blood. 3: 1069-77.